Sjogren's and Small Fiber Neuropathy: Diagnosis, Symptoms, and Treatment

Small fiber neuropathy (SFN) is the most common neurological complication of Sjogren's syndrome, affecting an estimated 40–60% of patients. Yet it remains one of the most underdiagnosed conditions in rheumatology — partly because standard nerve conduction studies (NCS) are normal in SFN, and partly because the symptoms overlap with fibromyalgia, anxiety, and other common diagnoses.

Understanding the relationship between Sjogren's and SFN is critical for patients who have been told their nerve tests are normal but continue to experience burning pain, autonomic symptoms, and profound fatigue.

What Is Small Fiber Neuropathy?

The peripheral nervous system contains two broad categories of nerve fibers:

• Large myelinated fibers — carry proprioception (position sense) and vibration; tested by standard nerve conduction studies
• Small fibers — carry pain, temperature, and autonomic signals; NOT tested by standard NCS

Small fiber neuropathy is damage specifically to these small fibers — the Aδ (lightly myelinated) and C (unmyelinated) fibers. Because standard NCS only test large fibers, SFN is invisible to the most commonly ordered nerve test, leading to years of diagnostic delay.

How Sjogren's Causes SFN

In Sjogren's syndrome, small fiber damage occurs through several mechanisms:

Direct immune attack — Anti-SSA/Ro and anti-SSB/La antibodies, as well as other autoantibodies, can directly target small nerve fibers and the dorsal root ganglia (the cell bodies of sensory neurons).

Inflammatory infiltration — Lymphocytic infiltration of the peripheral nervous system, similar to the glandular infiltration that causes sicca symptoms, damages small nerve fibers.

Vasculitis — Inflammation of the small blood vessels supplying peripheral nerves (vasa nervorum) causes ischemic nerve damage.

Cytokine-mediated damage — The pro-inflammatory cytokine environment in Sjogren's (elevated IL-6, TNF-α, type I interferons) is directly toxic to small nerve fibers.

Symptoms of SFN in Sjogren's

The symptoms of SFN in Sjogren's can be divided into sensory and autonomic components:

Sensory symptoms:

• Burning pain — often described as "feet on fire," particularly at night
• Allodynia — pain from normally non-painful stimuli (light touch, clothing contact)
• Hyperalgesia — exaggerated pain response to painful stimuli
• Tingling and numbness — typically in a length-dependent pattern (feet first, then hands)
• Electric shock sensations — brief, lancinating pains
• Temperature dysregulation — abnormal perception of hot and cold

Autonomic symptoms:

• Orthostatic intolerance / POTS — from autonomic fiber damage
• Sweating abnormalities — reduced sweating (anhidrosis) or excessive sweating
• Gastrointestinal symptoms — nausea, bloating, constipation from enteric autonomic damage
• Bladder dysfunction — urgency, frequency, incomplete emptying
• Dry eyes and dry mouth — both sicca features AND autonomic gland dysfunction contribute

Diagnosis

Skin punch biopsy — the gold standard:

The definitive test for SFN is a skin punch biopsy measuring intraepidermal nerve fiber density (IENFD). A 3mm punch biopsy is taken from the distal leg (10 cm above the lateral malleolus) and stained with anti-PGP9.5 antibody to visualize small nerve fibers. A density below the age- and sex-adjusted normative value confirms SFN.

Biopsies from multiple sites (distal leg, proximal thigh, distal thigh) can help determine whether the neuropathy is length-dependent (dying-back pattern, typical of metabolic causes) or non-length-dependent (patchy pattern, more typical of immune-mediated causes like Sjogren's).

QSART (Quantitative Sudomotor Axon Reflex Test):

QSART measures the function of the sudomotor (sweat-regulating) small fibers at four sites on the body. Abnormal results confirm autonomic small fiber involvement and help localize the level of damage.

Corneal confocal microscopy:

An emerging non-invasive technique that images the small nerve fibers of the cornea. Reduced corneal nerve fiber density correlates with SFN severity and may eventually replace skin biopsy as a diagnostic tool.

Serology:

• Anti-SSA/Ro, anti-SSB/La, ANA, RF — to confirm or screen for Sjogren's
• Anti-trisulfated heparin disaccharide (TS-HDS) and anti-fibroblast growth factor receptor 3 (FGFR3) antibodies — emerging markers for immune-mediated SFN

Treatment

Disease-modifying treatment:

Treating the underlying Sjogren's is the most important intervention for SFN. Options include:

• Hydroxychloroquine — reduces systemic inflammation; may slow SFN progression
• IVIG — the most evidence-based treatment for immune-mediated SFN; studies show improvement in nerve fiber density and symptom scores with regular infusions
• Rituximab — B-cell depletion; evidence for benefit in Sjogren's neuropathy
• Corticosteroids — for acute inflammatory flares

Symptomatic pain management:

• Duloxetine (Cymbalta) — SNRI with evidence for neuropathic pain; also addresses the fatigue and mood component
• Pregabalin (Lyrica) / Gabapentin — reduce neuronal excitability and burning pain
• Topical lidocaine or capsaicin — for localized burning pain
• Low-dose naltrexone (LDN) — emerging evidence for neuroinflammation and neuropathic pain
• Tricyclic antidepressants (amitriptyline, nortriptyline) — particularly helpful for nocturnal burning pain

Autonomic symptom management:

The autonomic symptoms of SFN are managed the same way as other forms of dysautonomia — increased salt and fluid intake, compression garments, positional strategies, and medications such as fludrocortisone, midodrine, or beta-blockers for POTS.

Key Takeaways

Small fiber neuropathy is a common, underdiagnosed, and treatable complication of Sjogren's syndrome. Standard nerve conduction studies will be normal — the diagnosis requires skin punch biopsy or QSART. Treatment targeting the underlying autoimmune process (particularly IVIG) can stabilize or improve nerve fiber density. Symptomatic management of pain and autonomic symptoms significantly improves quality of life.

This article is for educational purposes only and does not constitute medical advice.